How should hypothyroidism and an acute pseudogout attack be treated?

Management of Hypothyroidism and Acute Pseudogout

For a patient with hypothyroidism experiencing an acute pseudogout attack, treat the pseudogout attack immediately with first-line anti-inflammatory therapy (corticosteroids, NSAIDs, or colchicine) while continuing thyroid hormone replacement at the appropriate dose for the hypothyroidism. These are two separate conditions requiring concurrent but independent management.

Acute Pseudogout Treatment

The acute crystal-induced arthritis should be treated identically to gout, following established guidelines for calcium pyrophosphate deposition (CPPD) disease 1.

First-Line Options (Choose Based on Contraindications):

Corticosteroids (preferred for safety profile):

• Intra-articular injection: Triamcinolone acetonide 10-60 mg (dose varies by joint size) for monoarticular or oligoarticular involvement 1
• Oral: Prednisone 0.5 mg/kg/day for 5-10 days, then stop OR 30-35 mg/day for 3-5 days 2, 3
• Intramuscular: Triamcinolone acetonide 60 mg as single dose 1

NSAIDs (if no renal, cardiac, or GI contraindications):

• Full FDA-approved dose (e.g., naproxen, indomethacin, diclofenac) continued until complete resolution 2, 4
• Add proton pump inhibitor for GI protection where indicated 2

Colchicine (if started within 12-36 hours of symptom onset):

• Loading dose: 1.2 mg, then 0.6 mg one hour later 4, 3
• Avoid in severe renal impairment or if patient is on strong CYP3A4/P-glycoprotein inhibitors 3

Important Caveats for Pseudogout:

The evidence base for pseudogout treatment is extrapolated primarily from gout studies, as direct RCTs in CPPD are limited 1. However, clinical experience supports identical anti-inflammatory approaches. Corticosteroids are particularly effective and safe for acute CPPD attacks 1, with one study showing 100% pain relief within 48 hours using intra-articular triamcinolone.

Combination Therapy for Severe Attacks:

For severe polyarticular pseudogout (pain ≥7/10 or multiple large joints involved):

• Combine colchicine + NSAIDs, OR
• Oral corticosteroids + colchicine, OR
• Intra-articular steroids + any oral agent 2

Do not combine NSAIDs with systemic corticosteroids due to synergistic GI toxicity risk 2.

Hypothyroidism Management

Continue levothyroxine at the dose that maintains TSH in the normal range (typically 0.5-5.0 mIU/L) 5, 6. The hypothyroidism and pseudogout are managed as separate entities.

Key Considerations:

• Levothyroxine remains standard of care for hypothyroidism treatment 5
• Dose adjustments should be based on TSH levels, not the presence of pseudogout
• There is no clinically significant association between treated hypothyroidism and gout/pseudogout risk (adjusted OR 1.12) 7
• Newly initiated or recently increased thyroid replacement may transiently trigger pseudogout attacks 8, but this should not alter thyroid management once appropriate dosing is established

Monitoring:

• Check TSH 6-8 weeks after any levothyroxine dose change
• Target TSH to normal range (typically 0.5-5.0 mIU/L for most patients)
• Note: Xanthine oxidase inhibitors (allopurinol, febuxostat) can increase TSH levels in a dose-dependent manner 9, though this is not relevant for acute pseudogout management

Prophylaxis Considerations

Unlike gout, prophylactic colchicine for recurrent pseudogout has limited evidence 1. One uncontrolled trial showed colchicine 0.6 mg twice daily reduced attack frequency from 3.2 to 1.0 episodes per year 1. Consider prophylaxis only if:

• Recurrent attacks (≥2-3 per year)
• Patient can tolerate low-dose colchicine (0.5-0.6 mg once or twice daily)
• No severe renal impairment or drug interactions

There is no equivalent to urate-lowering therapy for CPPD - no agents effectively reduce calcium pyrophosphate crystal burden 10.

Common Pitfalls to Avoid:

1. Do not delay treatment waiting for joint aspiration if pseudogout is clinically suspected - treat empirically while pursuing diagnosis 3
2. Do not withhold or reduce levothyroxine due to pseudogout attack - these conditions are managed independently
3. Do not use intra-articular or systemic steroids if septic arthritis is suspected - always aspirate to exclude infection first 11
4. Avoid colchicine in severe renal impairment (CrCl <30 mL/min) or with strong drug interactions 3
5. Avoid NSAIDs in patients with renal disease, heart failure, or cirrhosis 4